期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 154, 期 -, 页码 102-122出版社
ELSEVIER
DOI: 10.1016/j.addr.2020.07.002
关键词
Liposomes; Lipid nanoparticulate; Microfluidics; Leciplex; Phospholipids; Cationic liposomes; Nanomedicine; Monoclonal antibody; Oligonucleotide; Targeted delivery
Liposomes are well recognised as effective drug delivery systems, with a range of products approved, including follow on generic products. Current manufacturing processes used to produce liposomes are generally complex multi-batch processes. Furthermore, liposome preparation processes adopted in the laboratory setting do not offer easy translation to large scale production, which may delay the development and adoption of new liposomal systems. To promote advancement and innovation in liposome manufacturing processes, this review considers the range of manufacturing processes available for liposomes, from laboratory scale and scale up, through to large-scale manufacture and evaluates their advantages and limitations. The regulatory considerations associated with the manufacture of liposomes is also discussed. New innovations that support leaner scalable technologies for liposome fabrication are outlined including self-assembling liposome systems and microfluidic production. The critical process attributes that impact on the liposome product attributes are outlined to support potential wider adoption of these innovations. (C) 2020 Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据